Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3764968
Max Phase: Preclinical
Molecular Formula: C43H58F2N6O8
Molecular Weight: 824.97
Molecule Type: Small molecule
Associated Items:
ID: ALA3764968
Max Phase: Preclinical
Molecular Formula: C43H58F2N6O8
Molecular Weight: 824.97
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H]1C[C@H]2C(=O)O[C@@H](C)[C@H](NC(=O)[C@H](Cc3cc(F)cc(F)c3)NC(=O)/C=C/CC3CCCCC3)C(=O)N3CCC[C@H]3C(=O)N3CCCC[C@H]3C(=O)N[C@@H](C)C(=O)N2C1
Standard InChI: InChI=1S/C43H58F2N6O8/c1-25-19-35-43(58)59-27(3)37(48-38(53)32(22-29-20-30(44)23-31(45)21-29)47-36(52)16-9-13-28-11-5-4-6-12-28)42(57)50-18-10-15-34(50)41(56)49-17-8-7-14-33(49)39(54)46-26(2)40(55)51(35)24-25/h9,16,20-21,23,25-28,32-35,37H,4-8,10-15,17-19,22,24H2,1-3H3,(H,46,54)(H,47,52)(H,48,53)/b16-9+/t25-,26+,27+,32+,33+,34+,35+,37+/m1/s1
Standard InChI Key: ATSCIXMSWGWYKG-GTWXMUPQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 824.97 | Molecular Weight (Monoisotopic): 824.4284 | AlogP: 3.06 | #Rotatable Bonds: 8 |
Polar Surface Area: 174.53 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 14 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.13 | CX Basic pKa: | CX LogP: 3.35 | CX LogD: 3.35 |
Aromatic Rings: 1 | Heavy Atoms: 59 | QED Weighted: 0.27 | Np Likeness Score: 0.48 |
1. Goodreid JD, Janetzko J, Santa Maria JP, Wong KS, Leung E, Eger BT, Bryson S, Pai EF, Gray-Owen SD, Walker S, Houry WA, Batey RA.. (2016) Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity., 59 (2): [PMID:26818454] [10.1021/acs.jmedchem.5b01451] |
Source(1):